We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Global Market for Diabetes Therapeutics and Diagnostics

By HospiMedica staff writers
Posted on 15 Apr 2008
The global market for diabetes therapeutics and diagnostics is estimated at US$214 billion in 2008. More...
This is expected to increase to more than $242 billion by 2013, a compound average annual growth rate of 2.5%. These are the findings of BCC Research (Wellesley, MA, USA), a publisher of market research reports and technical publications.

The global diabetes market is slated to become one of the largest healthcare markets over the next five years. The estimated 246 million people worldwide afflicted with diabetes at the end of 2007 demand healthcare products and services to manage this multi-factored and heterogeneous condition and its complications, and as such, the next five years promise to be a dynamic time for the global diabetes market. Industry leaders are expected to overcome technology barriers to bring non-invasive, insulin-based products to the market; software and data mining technologies continue to work in the market's favor by setting up a prototype of an artificial pancreas; and sales of insulin infusion pumps and lancing devices that feature a continuous glucose monitoring system are expected to be strong. These improved technologies should make prices more affordable to consumers.

The market can be broken down into applications of therapeutics, diagnostics, and all other interventions, which are the largest share of the market, expected to achieve an average annual growth rate of 2%. The second largest segment, therapeutics, and the diagnostics segment are expected to enjoy an average annual growth rate of 3%.

Diabetes, which already affects 246 million people worldwide, has zoomed from 30 million only two decades ago, leading to it being referred to as "the epidemic of the 21st century.” By the year 2025, it is expected to affect nearly 400 million people, about 7% of the world's adult population. Diabetes kills 3.8 million people a year - as many people as HIV/AIDS. Wherever poverty and a lack of sanitation drive families to low cost-per-calorie foods and packaged drinks, Type 2 diabetes thrives, according to a statement by the International Diabetes Federation (Brussels, Belgium). India and China currently have the highest number of diabetics, at around 40 million each. Type 2 diabetes is spreading the fastest in the Eastern Mediterranean and Middle East.


Related Links:
BCC Research
International Diabetes Federation

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.